Highlights Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
3.38 ^USD	-6.11%		-1.74%	-72.01%

May. 16	Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	CI
May. 15	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	May. 16	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	Feb. 22	CI
Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	Jan. 02	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study	23-08-01	CI
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	23-07-27	CI
Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol	23-07-25	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
North American Morning Briefing : China Data Helps Support Sentiment	23-04-18	DJ
Avenue Therapeutics, Inc. Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of Iv Tramadol	23-04-17	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist	23-03-09	DJ
Avenue Therapeutics Signs License Agreement to Develop, Commercialize Kennedy's Disease Treatment	23-03-02	MT
Avenue Therapeutics, Inc. Enters into A License Agreement with Annji Pharmaceutical Co. Ltd	23-03-02	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (ATXI) AVENUE THERAPEUTICS Reports Q3 Loss $-0.45	22-11-10	MT
Avenue Therapeutics, Inc. acquired Baergic Bio, Inc from Fortress Biotech, Inc.	22-11-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Highlights

Filters